Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
News|Articles|September 15, 2026
WCLC 2026: The Presentations That May Shape The Future of NSCLC
Author(s)Russ Conroy
Fact checked by: Ariana Pelosci
New data on antibody drug conjugates and extended survival follow-ups may inform clinical decision-making surrounding non–small cell lung cancer.
Advertisement
Advertisement
Experts in thoracic oncology have convened at Seoul, South Korea, to share critical advances in the treatment of patients with lung cancer as part of the
Related to this article
The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Advertisement
Advertisement